Arch Biopartners Inc.
ACHFF · OTC
9/30/2024 | 9/30/2023 | 9/30/2022 | 9/30/2021 | |
|---|---|---|---|---|
| Revenue | $2 | $2 | $1 | $4 |
| % Growth | 7% | 105.7% | -75.2% | – |
| Cost of Goods Sold | $4 | $2 | $1 | $4 |
| Gross Profit | -$2 | -$0 | -$1 | -$0 |
| % Margin | -78% | -6.5% | -52.1% | -3.9% |
| R&D Expenses | $4 | $2 | $1 | $4 |
| G&A Expenses | $0 | $3 | $1 | $1 |
| SG&A Expenses | $2 | $3 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$3 | -$1 | -$1 | -$3 |
| Operating Expenses | $2 | $3 | $1 | $1 |
| Operating Income | -$4 | -$3 | -$1 | -$1 |
| % Margin | -186% | -169.1% | -144% | -30% |
| Other Income/Exp. Net | $0 | $0 | -$0 | -$0 |
| Pre-Tax Income | -$4 | -$3 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4 | -$3 | -$1 | -$1 |
| % Margin | -184.7% | -167.7% | -146% | -30.1% |
| EPS | -0.062 | -0.053 | -0.023 | -0.019 |
| % Growth | -15.9% | -134.8% | -18.8% | – |
| EPS Diluted | -0.062 | -0.053 | -0.023 | -0.019 |
| Weighted Avg Shares Out | 63 | 62 | 62 | 61 |
| Weighted Avg Shares Out Dil | 63 | 62 | 62 | 61 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $3 | -$0 | $1 | $0 |
| EBITDA | $0 | -$3 | -$1 | -$1 |
| % Margin | 0% | -150.2% | -112% | -22.9% |